ES2269141T3 - Disulfuros ciclicos de pirrolidincarbonilamino como antagonistas de vcam-vla4. - Google Patents

Disulfuros ciclicos de pirrolidincarbonilamino como antagonistas de vcam-vla4. Download PDF

Info

Publication number
ES2269141T3
ES2269141T3 ES00929365T ES00929365T ES2269141T3 ES 2269141 T3 ES2269141 T3 ES 2269141T3 ES 00929365 T ES00929365 T ES 00929365T ES 00929365 T ES00929365 T ES 00929365T ES 2269141 T3 ES2269141 T3 ES 2269141T3
Authority
ES
Spain
Prior art keywords
compound
amino
acid
pharmaceutically acceptable
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00929365T
Other languages
English (en)
Spanish (es)
Inventor
Li Chen
Nader Fotouhi
David Young Jackson
Jefferson Wright Tilley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2269141T3 publication Critical patent/ES2269141T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES00929365T 1999-04-20 2000-04-17 Disulfuros ciclicos de pirrolidincarbonilamino como antagonistas de vcam-vla4. Expired - Lifetime ES2269141T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13021599P 1999-04-20 1999-04-20
US130215P 1999-04-20

Publications (1)

Publication Number Publication Date
ES2269141T3 true ES2269141T3 (es) 2007-04-01

Family

ID=22443611

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00929365T Expired - Lifetime ES2269141T3 (es) 1999-04-20 2000-04-17 Disulfuros ciclicos de pirrolidincarbonilamino como antagonistas de vcam-vla4.

Country Status (15)

Country Link
US (1) US6265572B1 (enExample)
EP (1) EP1171452B1 (enExample)
JP (1) JP2002542256A (enExample)
KR (1) KR100636481B1 (enExample)
CN (1) CN1167710C (enExample)
AR (1) AR023546A1 (enExample)
AT (1) ATE337331T1 (enExample)
AU (1) AU769294B2 (enExample)
BR (1) BR0009838A (enExample)
CA (1) CA2370259A1 (enExample)
DE (1) DE60030266T2 (enExample)
ES (1) ES2269141T3 (enExample)
TR (1) TR200103004T2 (enExample)
WO (1) WO2000063234A2 (enExample)
ZA (1) ZA200108018B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6939855B2 (en) * 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
US20090043126A1 (en) * 2005-02-28 2009-02-12 Jordi Bosch I Llado Process and Methods for the Preparation of Gabapentin and Its Intermediates
EP2510941A3 (en) 2007-02-20 2013-01-23 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
BRPI0911652A2 (pt) 2008-04-11 2015-08-04 Merrimack Pharmaceuticals Inc Ligantes de albumina sérica humana e seus conjugados
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
MX2014004025A (es) 2011-10-17 2014-08-01 Univ Muenster Wilhelms Metodos de valoracion de riesgo de lmp y aparatos relacionados.
WO2014036520A1 (en) 2012-08-30 2014-03-06 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
KR102630416B1 (ko) 2018-10-30 2024-02-01 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
ES3013256T3 (en) 2018-10-30 2025-04-11 Gilead Sciences Inc Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
CN114222730B (zh) 2019-08-14 2024-09-10 吉利德科学公司 用于抑制α4β7整合素的化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds

Also Published As

Publication number Publication date
ATE337331T1 (de) 2006-09-15
DE60030266T2 (de) 2007-07-19
CA2370259A1 (en) 2000-10-26
US6265572B1 (en) 2001-07-24
CN1347419A (zh) 2002-05-01
EP1171452B1 (en) 2006-08-23
AR023546A1 (es) 2002-09-04
BR0009838A (pt) 2002-01-08
AU4748200A (en) 2000-11-02
KR100636481B1 (ko) 2006-10-18
KR20010108517A (ko) 2001-12-07
TR200103004T2 (tr) 2002-01-21
WO2000063234A2 (en) 2000-10-26
AU769294B2 (en) 2004-01-22
DE60030266D1 (de) 2006-10-05
ZA200108018B (en) 2003-03-26
JP2002542256A (ja) 2002-12-10
EP1171452A2 (en) 2002-01-16
WO2000063234A3 (en) 2001-01-18
CN1167710C (zh) 2004-09-22

Similar Documents

Publication Publication Date Title
ES2274201T3 (es) Agonistas del receptor de melanocortina.
ES2336009T3 (es) Inhibidores de la ns-3 serina proteasa del vhc.
ES2214728T3 (es) Derivados de n-aroilfenilalanina.
ES2221197T3 (es) Derivados de n-alcanoilfenilalanina.
TWI283240B (en) VLA-4 inhibitor compounds
US5688946A (en) Amino acid derivatives having renin inhibiting activity
AU592768B2 (en) Novel 5-amino-4-hydroxyvaleryl derivatives
ES2299850T3 (es) Proceso y compuestos intermedios para la preparacion de (1r,2s,5s)-3-azabiciclo(3,1,0)hexano-2-carboxamida, n-(3-amino-1-(ciclobutilmetil)-2,3-dioxopropil)-3-((2s)-2-(((1,1-dimetiletil)amino)carbonilamino)-3,3-dimetil-1-oxobutil)-6,6-dimetilo.
CA2355630A1 (en) Compounds useful in the treatment of inflammatory diseases
CN103827108B (zh) 丙型肝炎病毒抑制剂
AU2008229725A1 (en) Beta-secretase inhibitors and methods of use
JP7429726B2 (ja) α４β７インテグリンを標的とする環状ペプチド多量体
JPH0323560B2 (enExample)
SK1694A3 (en) Pyrolidine derivatives, preparation thereof and drugs containing same
AU769294B2 (en) Pyrrolidincarbonylamino cyclic disulfides
CA2940455A1 (en) Polymyxin derivatives and their use in combination therapy together with different antibiotics
AU642046B2 (en) N-(2-alkyl-3-mercaptoglutaryl)-amino-diaza cycloalkanone derivatives and their use as collagenase inhibitors
US6706753B2 (en) Integrin receptor inhibitors
ES2359302T3 (es) Un proceso para preparar un derivado de fenilalanina e intermedios de los mismos.
JP6333826B2 (ja) アザインドリン
ES2219105T3 (es) Derivados de tan-1057.
ES2280566T3 (es) Macrociclos antibacterianos.
KR0125923B1 (ko) 고리형 화합물
MXPA01010543A (en) Pyrrolidincarbonylamino cyclic disulfides
US20030191053A1 (en) Cyclic peptide derivative